Related Experiment Videos
Cardiomyocyte injury to transplant: pediatric management
Gul H Dadlani1, William G Harmon, Valeriano C Simbre II
1Division of Pediatric Cardiology, Golisano Children's Hospital at Strong, University of Rochester School of Medicine and Dentistry, New York 14642, USA.
Insights
Pediatric heart failure and transplantation management differs from adults. Evidence-based reviews highlight the need for pediatric-specific clinical trials on new therapies for better outcomes.
Area of Science:
- Pediatric Cardiology
- Cardiovascular Research
- Transplantation Medicine
Background:
- Pediatric cardiomyocyte injury causes differ from adult heart failure.
- Current pediatric heart failure and transplantation management often relies on adult study data.
- Emerging therapies for neurohormonal regulation and immunosuppression show promise.
Purpose of the Study:
- To review current evidence-based recommendations for pediatric heart failure management.
- To examine medical management strategies for myopathic dysfunction in children.
- To assess current approaches to pediatric heart transplantation and immunosuppression.
Main Methods:
- Review of existing literature and evidence-based medicine.
- Analysis of current treatment guidelines for pediatric heart failure.
- Examination of data on novel therapeutic agents in pediatric populations.
Main Results:
- Limited pediatric-specific clinical trial data exists for many treatments.
- Management strategies are often extrapolated from adult cardiology studies.
- New neurohormonal and immunosuppression therapies require further pediatric investigation.
Conclusions:
- Pediatric heart failure and transplantation require distinct therapeutic approaches.
- Large, randomized, multicenter trials are essential to validate new therapies in pediatric patients.
- Evidence-based medicine should guide current management while awaiting pediatric-specific trial results.
Abstract:
Cardiomyocyte injury in pediatric patients has a vast number of causes, which are often distinct from the causes of adult heart failure. However, the management of pediatric heart failure and heart transplantation has generally been inferred from adult studies. New therapies show great promise for the neurohormonal regulation of heart failure and the ability to control immunosuppression after heart transplantation. Large, randomized, multicenter, controlled clinical trials are needed to determine the efficacy of these therapies in this population. This article reviews the current recommendations and evidence-based medicine, where available, for the medical management of myopathic dysfunction and transplantation in pediatric patients.